All In Biotech

NDA 020834 · Kenvue Brands

Rogaine Extra Strength (For Men)

Minoxidil · Topical · Arteriolar Vasodilator

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Nov 14, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

93

21 Phase 3, 12 recruiting

FAERS reports

33,735

4,726 serious, 453 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 9, 2026.

Use to regrow hair on the top of the scalp (vertex only, see pictures on side of carton)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 14, 1997 Original approval · Type 3 - New Dosage Form Review
1 products under this application
  • ROGAINE EXTRA STRENGTH (FOR MEN) · MINOXIDIL 5% · SOLUTION, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Minoxidil" as an intervention, any sponsor and status, largest first.

All 93 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • adverse drug reaction8,609
  • drug ineffective6,323
  • application site pruritus2,582
  • off label use1,521
  • application site irritation1,251
  • headache1,112
  • application site pain1,110
  • alopecia986
  • inappropriate schedule of product administration826
  • application site dryness747
  • condition aggravated736
  • product administered at inappropriate site705

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200495
2005122
2006128
200789
2008113
2009130
2010149
2011167
2012219
2013152
2014196
2015589
2016829
2017796
20181,115
20191,176
20202,457
20214,839
20227,986
20235,654
20243,111
20252,226
20261,397

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 380 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.